Is SKWD a Buy or a Sell? The Bull and Bear Case (2026)

The most optimistic published target on SKWD is $80.00, +40.6% from the $56.89 price as of August 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

The most pessimistic published target is $56.00, -1.6% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Skyward Specialty Insurance is worth if the risks below bite instead of the drivers above.

The largest exposure is reserve adequacy. Net loss reserves of ~$1,908.1M exceed shareholders' equity of ~$1,267.5M by half again, so a 5% deficiency across the book would consume roughly 7% of book value before tax. Growth compounds that: Global Agriculture premium nearly doubled year over year and Accident & Health rose 57.8%, and immature accident years in fast-growing lines are where estimation error tends to appear two or three years later. A second, less discussed exposure is credit. Reinsurance recoverables of ~$1,411.6M are larger than the entire equity base, and Skyward remains liable to policyholders if a reinsurer fails to pay. The company has also been retaining more risk itself, with net retention on a written basis rising to 65.6% in the second quarter of 2026 from 58.0% a year earlier, which raises the loss volatility that reaches the income statement. Apollo brings its own set. Goodwill and intangibles of ~$471.2M now equal ~37% of equity, including $200M of indefinite-lived syndicate capacity that is tested for impairment rather than amortised, and the 10-Q states that the assessment of internal control over financial reporting excludes Apollo while integration continues. The Lloyd's segment ran a 97.6% combined ratio in the quarter with 5.4 points of catastrophe loss attributed primarily to the conflict in the Middle East, a reminder that the acquired book carries political and war exposure the US divisions largely do not. Pricing is the background condition: management's own 2026 guidance assumes a 90.5% to 91.5% combined ratio, above the 89.5% delivered in the first half, which implies an expected second-half deterioration. Alternative and strategic investments have been a persistent drag, costing ~$8.1M in the first half of 2026 after ~$11.5M in 2025. Chief Financial Officer Mark Haushill is retiring effective March 31, 2027.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding SKWD already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

11 analysts cover SKWD, with an average target of $70.55 (+24.0% against $56.89) and a split of 9 buy, 4 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the SKWD forecast and price target page.

• Revenue (TTM): ~$1.73B for the twelve months to June 30, 2026, against ~$1.42B in fiscal 2025, ~$1.15B in 2024 and ~$886M in 2023. The 2026 half-year figure of ~$965.4M includes Apollo for the first time, alongside ~$878.5M of net earned premium, ~$57.8M of net investment income, ~$22.7M of underwriting fee income and ~$3.9M of commission and fee income.
• Earnings and operating earnings: Second-quarter 2026 net income of ~$49.0M, or ~$1.07 per diluted share, and operating income of ~$59.2M, or ~$1.30 per diluted share, up 46% year over year. First-half net income was ~$98.8M (~$2.17 diluted) and operating income ~$116.1M (~$2.55 diluted). Full-year 2025 delivered ~$170.0M of net income (~$4.07 diluted) and ~$167.4M of adjusted operating income (~$4.00). Trailing twelve-month diluted EPS is ~$4.30.
• Underwriting metrics: Combined ratio of 89.5% in the second quarter of 2026 (62.3% loss, 27.2% expense), 87.6% excluding 1.9 points of catastrophe loss, versus 89.3% for full-year 2025 and 92.3% for 2024. By segment, Skyward Specialty ran 86.9% and Apollo 97.6%. Gross written premiums were ~$740.6M in the quarter and ~$2,166.2M for full-year 2025; ceded written premium of ~$254.9M in the quarter left ~$485.6M net written and ~$444.5M net earned, a 65.6% net retention.
• Book value and returns: Book value per share of $28.55 at June 30, 2026, up 14.6% from $24.92 at December 31, 2025, which had itself risen 26% during 2025. Fully diluted book value per share was $27.20 and tangible shareholders' equity ~$861.9M, or roughly $19.41 per share. Annualized return on equity was 15.7% for the quarter and 17.3% for the half; annualized operating ROE was 19.0% and 20.4%, and operating return on tangible equity 28.2% and 26.0%.
• Balance sheet: Total assets of ~$6.78B at June 30, 2026 against ~$4.79B at year-end 2025, reflecting the Apollo consolidation. Investments totalled ~$2.74B with ~$219.2M of cash, ~$83.3M restricted cash and ~$121.6M of Funds at Lloyd's. Reserves for losses and loss adjustment expenses were ~$3.07B gross and ~$1.91B net; reinsurance recoverables ~$1.41B. Debt stood at ~$417.6M of notes payable plus ~$19.6M of subordinated notes after a $50.0M term loan repayment in June, against ~$1,267.5M of equity.
• Market pricing: Shares trade near ~$56.89 for a market value of ~$2.5B on ~44.4M shares outstanding, within a 52-week range of ~$40.60 to ~$65.69. The stock therefore changes hands at ~13x trailing diluted earnings, ~2.0x book value and ~2.9x tangible book, and roughly 12x the $4.50 to $4.70 of 2026 net income per diluted share the company guided to in December 2025. No dividend is paid. Reported beta is ~0.33. Published analyst price targets average ~$70.55.

A screener's 1.3x price-to-sales figure carries almost no signal for SKWD, because insurance revenue is premium the company has already promised to pay claims against. The multiple that carries information is price to book, and at ~2.0x the stock sits well below the ~4x to 5x that the market has awarded the fastest-growing US excess and surplus underwriters, and above the ~1.3x to 1.5x typical of carriers whose returns hover near their cost of capital. On tangible book the gap narrows, since ~$471.2M of the equity base is now goodwill and intangibles from Apollo.

Rather than asking whether SKWD is a buy in the abstract, it tends to help to answer four questions:

• Thesis: do you believe the bull case above, and is it still true today?
• Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
• Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
• Overlap: check whether you already hold SKWD indirectly through an index or sector ETF before adding more.

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

• Bull case breaks if: Apollo turns an underwriter into a fee earner as well stalls in the reported numbers rather than in the narrative around them.
• Bear case breaks if: the largest exposure is reserve adequacy fails to materialise over several reporting periods while the drivers keep compounding.
• Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the SKWD stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about SKWD against your real portfolio and see your actual exposure before deciding.